-
公开(公告)号：US20210025900A1
公开(公告)日：2021-01-28
申请号：US16923043
申请日：2020-07-07
Applicant: Biogen MA Inc.
Inventor： Meena Subramanyam , Lakshimi Amaravadi , Eric Wakshull , Frances Lynn , Michael Panzara , Robin McDaid Barbour , Julie Elizabeth Taylor
Abstract: The invention relates to methods and products for the identification of a clinically significant immune response in subjects treated with a therapeutic protein. Aspects of the invention relate to methods and compositions for identifying a clinically significant immune response in patients treated with therapeutic amounts of a VLA4 binding antibody (e.g., natalizumab).
-
Patent Agency Ranking
公开(公告)号：US20250020660A1
公开(公告)日：2025-01-16
申请号：US18426232
申请日：2024-01-29
Applicant: Biogen MA Inc.
Inventor： Meena Subramanyam , Lakshimi Amaravadi , Eric Wakshull , Frances Lynn , Michael Panzara , Robin McDaid Barbour , Julie Elizabeth Taylor
Abstract: The invention relates to methods and products for the identification of a clinically significant immune response in subjects treated with a therapeutic protein. Aspects of the invention relate to methods and compositions for identifying a clinically significant immune response in patients treated with therapeutic amounts of a VLA4 binding antibody (e.g., natalizumab).
-
公开(公告)号：US10705095B2
公开(公告)日：2020-07-07
申请号：US15616669
申请日：2017-06-07
Applicant: Biogen MA Inc.
Inventor： Meena Subramanyam , Lakshmi Amaravadi , Eric Wakshull , Frances Lynn , Michael Panzara , Robin McDaid Barbour , Julie Elizabeth Taylor
Abstract: The invention relates to methods and products for the identification of a clinically significant immune response in subjects treated with a therapeutic protein. Aspects of the invention relate to methods and compositions for identifying a clinically significant immune response in patients treated with therapeutic amounts of a VLA4 binding antibody (e.g., natalizumab).
-
公开(公告)号：US20180088127A1
公开(公告)日：2018-03-29
申请号：US15616669
申请日：2017-06-07
Applicant: Biogen MA Inc.
Inventor： Meena Subramanyam , Lakshmi Amaravadi , Eric Wakshull , Frances Lynn , Michael Panzara , Robin McDaid Barbour , Julie Elizabeth Taylor
Abstract: The invention relates to methods and products for the identification of a clinically significant immune response in subjects treated with a therapeutic protein. Aspects of the invention relate to methods and compositions for identifying a clinically significant immune response in patients treated with therapeutic amounts of a VLA4 binding antibody (e.g., natalizumab).
-
公开(公告)号：US11686734B2
公开(公告)日：2023-06-27
申请号：US16923043
申请日：2020-07-07
Applicant: Biogen MA Inc.
Inventor： Meena Subramanyam , Lakshimi Amaravadi , Eric Wakshull , Frances Lynn , Michael Panzara , Robin McDaid Barbour , Julie Elizabeth Taylor
CPC classification number: G01N33/6854 , C07K16/2839 , G01N33/686 , G01N2333/70546 , G01N2800/065 , G01N2800/102 , G01N2800/285 , G01N2800/52
Abstract: The invention relates to methods and products for the identification of a clinically significant immune response in subjects treated with a therapeutic protein. Aspects of the invention relate to methods and compositions for identifying a clinically significant immune response in patients treated with therapeutic amounts of a VLA4 binding antibody (e.g., natalizumab).
-
公开(公告)号：US09709575B2
公开(公告)日：2017-07-18
申请号：US14330619
申请日：2014-07-14
Applicant: Biogen MA Inc.
Inventor： Meena Subramanyam , Lakshmi Amaravadi , Eric Wakshull , Frances Lynn , Michael Panzara , Robin McDaid Barbour , Julie Elizabeth Taylor
CPC classification number: G01N33/6854 , C07K16/2839 , G01N33/686 , G01N2333/70546 , G01N2800/065 , G01N2800/102 , G01N2800/285 , G01N2800/52
Abstract: The invention relates to methods and products for the identification of a clinically significant immune response in subjects treated with a therapeutic protein. A first aspect of the invention relates to methods and compositions for identifying a clinically significant immune response in patients treated with therapeutic amounts of VLA4 binding antibody (e.g., natalizumab). A second aspect of the invention concerns the chronological details of sample collection for determining the titer of antibodies against the therapeutic protein, e.g. the collection of at least two samples at two different time points. A third aspect of the invention relates to the selection of the critical threshold level, which corresponds to the antibody titer of untreated patients increased by the double of the standard deviation of this control antibody titer.
-
-
-
-
-
Search Results
6
records
(took 0.017 seconds)
